Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
Harmony presents six posters at SLEEP 2026 on Phase 1b/3 trials of Pitolisant and HBS-301 for narcolepsy and idiopathic hypersomnia. Parallel advancement toward regulatory approval signals competitive momentum in rare neurological disease, a high-margin specialty pharma segment.
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), which will be held June 14 – 17 in Baltimore, MD.
The poster presentation details are as follows:
Abstract Title
Poster Presentation Session
Harmony Biosciences to Participate in Upcoming Investor Conferences
Clinical-stage biotech will present three posters highlighting Phase 2 results and Phase 3 plans for narcolepsy treatment.
Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea
JCR Pharmaceuticals’ Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026…
Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall…
Junevity to Present Breakthrough Research on siRNA Therapeutics at American Aging Association’s 2026 Annual Meeting
